← Leaderboards
Kyle D Holen
University Of Wisconsin-Madison
$17,817
Attributed
$17,817
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $16.8K · FY2006–07$20K$15K$10K$5K$0
'06
'07
Funding mix
By agency
NIH$17,817 · 3
By mechanism
M01$17,817 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Richard J Davidson$53,083,653
- Bruce Steven Klein$36,349,356
- Ned H Kalin$48,172,395
- James E. Gern$167,391,145
- Lianwang Guo$8,850,010
Others in their field
Top investigators on “Bevacizumab”
- Philip J Disaia · University Of California Irvine$37,377,674
- Walter John Curran · Thomas Jefferson University$26,641,549
- Keri, Hammel · The Emmes Company, Llc$11,064,901
- Ingrid U Scott · University Of Miami School Of Medicine$11,046,410
- Edward A Neuwelt · Oregon Health And Science University$10,237,023
- Raymond Kraker · Jaeb Center For Health Research, Inc.$10,221,413
Research focus
BevacizumabBevacizumab/ErlotinibSourceTumorTumor GrowthUnited States National Institutes Of HealthBlood FlowCell GrowthClinical Trials, Phase IiComputer Retrieval Of Information On Scientific Projects DatabaseEnzymesErlotinibFundingGrantGrowthInstitutionKillingsMonoclonal AntibodiesNeoplastic CellOther FindingResearch PersonnelResourcesBiliaryUnresectable
Grant awards (3)
PHASE II TRIAL OF BEVACIZUMAB AND ERLOTINIB IN ADVANCED BILIARY TUMORS$812
M01 · FY2007 · RR · contact PI
PHASE II STUDY OF BEVACIZUMAB PLUS ERLOTINIB IN ADVANCED HEPATOCELLULAR CANCER$249
M01 · FY2007 · RR · contact PI
PHASE II STUDY OF TRIAPINE FOR ADVANCED ADENOCARCINOMA OF THE PANCREAS$16,756
M01 · FY2006 · RR · contact PI